Taking into account the evidences of S100A9 as a mediator of resistance of BMs to radiotherapy,1 the inhibition of the S100A9–RAGE axis could be a novel approach to restore the sensitivity to this treatment in cancer patients with brain dissemination of the tumor. The gene discussed is S100A9; the disease is neoplasm.